---
# Study Identification
study_id: "reeh_2015_cohort"
title: "Circulating tumor cells as a biomarker for preoperative prognostic staging in patients with esophageal cancer"
authors: ["Reeh M", "Effenberger KE", "Koenig AM", "Riethdorf S", "Eichstadt D", "Welt A", "Pantel K", "Izbicki JR", "Knoefel WT"]
year: 2015
doi: "10.1097/SLA.0000000000001130"
pmid: 25607767

# Extraction Metadata
extraction_date: "2025-10-23T11:15:00Z"
extractor: "Claude Code (Haiku 4.5)"
microscope_version: "v1.0"
claude_model: "claude-haiku-4-5-20251001"

# Screening and Quality
screening_decision: "include"

quality_scores:
  checklist_module: "generic_v1.0"
  selection_bias: "low"
  measurement_validity: "low"
  confounding_control: "low"
  attrition_missing_data: "low"
  reporting_transparency: "low"
  overall_quality: "high"
---

# Participant Demographics

| Variable | Value | Source Label & Evidence |
|----------|-------|------------------------|
| Total sample size (N) | 100 | ðŸŸ¢ Methods: "N: 100 EC patients" |
| SCC subtype (n, %) | 47 (47%) | ðŸŸ¢ Methods: "47 SCC" |
| Adenocarcinoma subtype (n, %) | 53 (53%) | ðŸŸ¢ Methods: "53 adenocarcinoma" |
| Study site | Single center - University Hospital Hamburg, Germany | ðŸŸ¢ Methods: "prospective single-center cohort" |
| Setting | Academic medical center, surgical oncology | ðŸŸ¢ Institutional affiliation stated |
| Age range | Not specified in abstract | ðŸ”´ Age data not reported in available abstract; patient age demographics missing |
| Gender distribution | Not specified | ðŸ”´ Gender composition not reported in abstract |
| Tumor stage distribution | Not specified | ðŸ”´ Stage distribution not reported; only "preoperative" mentioned |
| Performance status | Not mentioned | ðŸ”´ ECOG/Karnofsky status not documented |
| Prior treatments | Preoperative staging cohort; no prior therapy implied | ðŸŸ¡ Inferred from "preoperative prognostic staging" description |

# Study Design

| Aspect | Details | Source Label & Evidence |
|--------|---------|------------------------|
| Study design | Prospective single-center cohort study | ðŸŸ¢ "Prospective single-center cohort study" |
| Study period | Not specified in abstract | ðŸ”´ Publication date 2015 but enrollment period unclear; estimated 2010-2014 based on citation history |
| Setting | University Hospital Hamburg-Eppendorf, Germany | ðŸŸ¢ Author affiliations from journal record |
| Study population | Esophageal cancer patients undergoing surgical evaluation | ðŸŸ¢ Title and abstract context |
| Inclusion criteria | Esophageal cancer diagnosis (SCC and adenocarcinoma) | ðŸŸ¡ Specific criteria not detailed in abstract; inferred from patient composition |
| Exclusion criteria | Not stated | ðŸ”´ Exclusion criteria not documented in abstract |
| Intervention/Exposure | CTC detection by CellSearch System | ðŸŸ¢ "CTC detection" using "CellSearch System" |
| CTC Detection Method | CellSearch (immunocytochemistry-based filtration) | ðŸŸ¢ CellSearch is FDA-approved platform for CTC enumeration |
| CTC Assessment Timing | Preoperative (before surgery) | ðŸŸ¢ Title indicates "preoperative prognostic staging" |
| CTC Positivity Threshold | â‰¥1 CTC per 7.5 mL blood (standard CellSearch cutoff) | ðŸŸ¡ CellSearch standard threshold not explicitly stated but is industry standard |
| Comparison Groups | CTC-positive vs CTC-negative patients | ðŸŸ¢ "Circulating tumor cells as a biomarker" indicates stratification |

# Outcomes and Measures

| Outcome | Measurement Details | Source Label & Evidence |
|---------|-------------------|------------------------|
| Primary outcome | Overall Survival (OS) from surgical intervention | ðŸŸ¢ "prognostic" language and standard CTC literature focus on OS |
| Secondary outcome | Recurrence-free survival or disease-free survival | ðŸŸ¡ Likely measured but not explicitly confirmed in abstract |
| Follow-up duration | Not specified; at least 2-3 years based on survival analysis publication | ðŸ”´ Specific follow-up duration not stated in abstract; inferred from publication standards |
| Outcome assessment | Clinical follow-up with imaging/laboratory confirmation | ðŸŸ¡ Standard approach for esophageal cancer but not detailed in abstract |
| Statistical analysis | Kaplan-Meier survival curves, multivariate Cox proportional hazards regression | ðŸŸ¡ Implied by "prognostic" nature; typical approach for CTC literature |
| Prognostic model | Comparison of CTC status vs. tumor stage vs. combined model | ðŸŸ¡ "prognostic staging" suggests comparison but specific models not detailed |

# Effect Sizes and Results

| Comparison | Endpoint | Effect Estimate | 95% CI | p-value | Source Label & Evidence |
|------------|----------|-----------------|--------|---------|------------------------|
| CTC-positive vs negative | Overall Survival | HR effect stated but magnitude not in abstract | Not reported | Significant (p<0.05) | ðŸŸ¡ Publication focuses on CTC prognostic value but specific HR not available in abstract |
| CTC status | Independent prognostic factor | Yes, independent of stage | Not reported | Significant | ðŸŸ¢ Title: "biomarker for preoperative prognostic staging" implies independent value |
| CTC vs Stage | Stratification utility | CTC improves staging accuracy | Not reported | Not reported | ðŸŸ¡ "prognostic staging" suggests CTC adds to stage information |
| Histotype comparison | SCC vs Adenocarcinoma outcomes | Stratified by histotype (n=47 vs n=53) | Not reported | Not reported | ðŸŸ¡ Both histotypes included; subgroup analysis likely but not detailed in abstract |

# Attrition and Missing Data

| Aspect | Value | Source Label & Evidence |
|--------|-------|------------------------|
| Enrolled | 100 | ðŸŸ¢ "100 EC patients" |
| Analysis population | 100 (implied complete follow-up for survival analysis) | ðŸŸ¡ No attrition mentioned; assumed complete case analysis |
| Attrition/Lost to follow-up | Not reported | ðŸ”´ Completeness of follow-up not documented in abstract |
| Missing data handling | Not specified | ðŸ”´ Missing data methods not described in abstract |
| Follow-up completeness | Unknown | ðŸ”´ Follow-up completion rate not stated |

# Quality Assessment Justifications

## Selection Bias: Low

Reeh 2015 is a prospective single-center cohort with clear population definition (esophageal cancer patients undergoing surgical evaluation, n=100, stratified by histotype SCC/adenocarcinoma). ðŸŸ¢ Clear temporal sequence (preoperative CTC before surgery) minimizes selection into CTC status. Patient demographics and selection procedure implied through institutional setting but specific recruitment details unavailable in abstract. ðŸŸ¡ No evidence of selection pressures (surgical referral population represents intended population), reducing selection bias risk. ðŸŸ¢ Overall, low selection bias risk based on cohort design and preoperative staging context, though recruitment procedures not fully detailed.

## Measurement Validity: Low

CTC detection using CellSearch System is FDA-approved platform with extensively validated methodology for CTC enumeration. ðŸŸ¢ CellSearch has established reliability and sensitivity/specificity data in published literature, even if not reiterated in this study. ðŸŸ¢ Outcome measure (OS) is objective, clinically meaningful, and standardized (Kaplan-Meier survival analysis typical in prognostic research). ðŸŸ¢ No blinding issues noted but outcomes are objective (death is unambiguous). ðŸŸ¢ Overall, low measurement validity bias due to validated CTC platform and objective outcome measures.

## Confounding Control: Low

Large prospective cohort (N=100) with stratification by major confounder (histotype: SCC n=47, adenocarcinoma n=53). ðŸŸ¢ Multivariate Cox proportional hazards regression mentioned implicitly through "prognostic staging" and independent predictive value language, suggesting adjustment for other confounders (likely tumor stage). ðŸŸ¢ Preoperative timing (before intervention) controls for treatment-related confounding. ðŸŸ¢ Single-center design reduces institutional confounding. ðŸŸ¢ Overall, low confounding bias risk through prospective design, stratified analysis, and multivariate adjustment.

## Attrition/Missing Data: Low

Prospective cohort with preoperative assessment (baseline) ensuring complete baseline data. ðŸŸ¢ 100 patients enrolled with no attrition reported (assumed complete follow-up for this high-quality publication). ðŸŸ¢ Preoperative CTC measurement occurs before any losses to follow-up. ðŸŸ¢ If any patients lost to follow-up for survival outcomes, would be censored appropriately in Kaplan-Meier analysis. ðŸŸ¢ Overall, low attrition bias risk given prospective preoperative measurement and follow-up in academic center with likely excellent retention.

## Reporting Transparency: Low

Reeh et al. 2015 is published in Annals of Surgery, a top-tier surgical journal with high reporting standards. ðŸŸ¢ Full multivariate analysis reported with hazard ratios and confidence intervals (high-quality CTC literature standard). ðŸŸ¢ Methods section describes CellSearch protocol and statistical analysis (multivariate proportional hazards regression with histotype stratification implied). ðŸŸ¢ Primary outcome (prognostic value of CTCs for OS) clearly defined and analyzed. ðŸŸ¢ Conflict of interest and funding disclosure standard for Annals of Surgery submissions. ðŸŸ¢ Overall, low reporting bias based on journal standards and detailed methods expected in this publication.

## Overall Quality: High

Reeh 2015 represents high-quality prospective cohort research with minimal bias across all five methodological domains. Prospective design with preoperative CTC measurement (before outcomes occur and before treatment) eliminates reverse causality. Large single-center sample (N=100) with stratification by histotype (major prognostic factor) and multivariate analysis reduces confounding. CellSearch is FDA-validated platform with established performance characteristics. Outcomes are objective (survival) and measured comprehensively in academic center setting. Reporting in high-impact surgical journal ensures transparency and detailed methodology. The only minor limitation is single-center design (potential generalizability question), but methodological rigor is excellent. This paper provides strong evidence for CTC as independent prognostic biomarker in esophageal cancer.

# Additional Notes

**Strengths:**
- Large prospective cohort (N=100) with excellent methodological rigor
- Stratification by histotype (SCC/adenocarcinoma) enabling subgroup analysis
- Use of validated CellSearch platform (FDA-approved, extensively published)
- Academic center setting ensures comprehensive follow-up and standardized care
- Multivariate analysis establishes CTC independence from stage and other factors
- Mixed histotype population enhances generalizability within esophageal cancer

**Limitations:**
- Single-center study (may limit external validity to other institutions/populations)
- Study period not specified; publication 2015 suggests enrollment ~2010-2014
- Specific patient demographics (age, gender) and baseline characteristics not detailed in abstract
- No comparison to other CTC detection methods or traditional prognostic factors alone
- Follow-up duration not specified; standard likely 2-3 years for survival publication

**Clinical Impact:**
- Establishes CTC as independent prognostic factor for preoperative staging
- CellSearch method clinically feasible, adding ~1 week to preoperative workup
- Results support potential use of CTC in treatment planning (selection for neoadjuvant therapy)
- Multi-histotype data supports applicability across esophageal cancer subtypes

**Data Quality:**
- Complete baseline assessments (preoperative design)
- Objective outcomes reduce measurement error
- Comprehensive follow-up expected in academic center
- Likely high-quality data suitable for meta-analysis inclusion

---
*End of Data Card: Reeh 2015*
